Effect of Lymph Node Ratio in Gastric Cancer to Determine Recurrence Rate After Curative Resection

NCT03778710 | Completed

• 1 other identifier: 2018/633
• Study Type: observational
• Target: 155
• Locations: 1 country
• Sites: 1

Brief Summary

D2 gastrectomy is standard treatment of early gastric cancer in Japan but in other countries there is still some discord, especially in Europe and North America. Although the quantity of metastasis cancer in lymph node defines survival regardless of which country the patient is treated, the total number of lymph nodes harvested is an important factor to predict accurate staging and/or D2 gastrectomy. Both of the number total lymph nodes and the metastasis lymph node status in gastric cancer are important factors to decide each prognosis. This study evaluated the correlation between total lymph nodes retrieved and metastasis node by lymph node ratio (LNR) status to determine the recurrence rate after curative resection of gastric

Conditions

Gastric Cancer

Keywords

Lymph node metastasis, Gastric cancer

Outcome Measures

Primary Outcomes (2)

• The correlation of lymph node ratio and survival of gastric cancer patients

  correlation of lymph node ratio and survival of gastric cancer patients.lymph node ratio was divided in to 5 ranges including 0.000-0.109, 0.110-0.209, 0.210-0.309, 0.410-0.609 and 0.610-1.000.

  5 year

• The correlation of lymph node ratio and prognosis of recurrence of gastric cancer patients

  correlation of lymph node ratio and recurrence of gastric cancer patients.lymph node ratio was divided in to 5 ranges including 0.000-0.109, 0.110-0.209, 0.210-0.309, 0.410-0.609 and 0.610-1.000.

  5 year

Secondary Outcomes (1)

• The correlation of total of lymph node retrieved less than 15 and more than 15 nodes and survival of gastric cancer patients

  5 year

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

All patients who presented with gastric cancer after curative surgery resection from January 1, 1995 to December 31, 2016 in Ramathibodi Hospital.

You may qualify if:

• Gastric cancer after curative surgery resection
• No received neoadjuvant therapy
• Patients have tissues confirmed by Pathology
• Staging used esophagogastroduodenoscopy (EGD) or imaging, including ultrasonography, Computer Tomography (CT) or Magnetic Resonance Imaging (MRI
• Surgery was performed for curative intent and D2 lymphadenectomy and according from Japanese guideline for gastric cancer

You may not qualify if:

• Distant metastasis during surgery

Sponsors & Collaborators

• Mahidol University: lead

Study Sites (1)

Chairat Supsamutchai

Bangkok, Bankok, 10400, Thailand

Location

MeSH Terms

Conditions

Stomach Neoplasms; Lymphatic Metastasis

Condition Hierarchy (Ancestors)

Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Stomach Diseases; Neoplasm Metastasis; Neoplastic Processes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Chairat Supsamutchai, MD

  Ramathibodi Hospital

  STUDY CHAIR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 16, 2018
• First Posted: December 19, 2018
• Study Start: December 18, 2018
• Primary Completion: January 30, 2019
• Study Completion: February 20, 2019
• Last Updated: March 26, 2019

Record last verified: 2019-03

Data Sharing

• IPD Sharing: Will not share

Locations

TH (1)